Research Article
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
Table 2
Characteristics of 124 TNBC patients assessed for BRCA1/2 mutations.
| Factor | Patients tested for BRCA mutations | value (BRCA-positive vs BRCA-negative) | BRCA noncarriers | Rate (%) | BRCA carriers | Rate (%) |
| Number of patients | 94 | 100 | 30 | 100 | |
| Age at diagnosis (years) | Median | 49 | | 40 | | 0.0115 | Mean | 47.5 | | 41.4 | | Range | 25–67 | | 24–76 | |
| Clinical staging (cTNM) | I | 23 | 24.5 | 14 | 47 | 0.0006 | II | 51 | 54 | 13 | 43 | III | 19 | 20 | 2 | 7 | IV | 1 | <0.5 | 1 | 3 |
| Initial clinical tumor staging | cT0 | 0 | 0 | 0 | 0 | 0.0004 | cT1 | 28 | 30 | 16 | 53 | cT2 | 56 | 59.5 | 9 | 30 | cT3 | 4 | 4 | 2 | 7 | cT4 | 6 | 6.5 | 3 | 10 | No available data | 0 | 0 | 0 | 0 |
| Initial clinical node staging | cN0 | 55 | 58.5 | 19 | 63 | 0.1063 | cN1 | 27 | 28.5 | 10 | 33 | cN2 | 9 | 9.5 | 1 | 4 | cN3 | 3 | 3.5 | 0 | 0 | No available data | 0 | 0 | 0 | 0 |
| HER2 expression | 0 or 1+ | 79 | 84 | 29 | 97 | 0.0091 | 2+, FISH negative | 15 | 16 | 1 | 3 |
| Histological type | NST | 80 | | 21 | 70 | 0.0023 | Lobular | 5 | 85 | 1 | 3.5 | Medullar | 5 | 5.5 | 1 | 3.5 | Apocrine | 2 | 5.5 | 1 | 3.5 | Metaplastic | 2 | 2 | 2 | 6 | Others | 0 | 2 | 4 | 13.5 |
| G | 1 | 0 | 0 | 2 | 6.5 | 0.0065 | 2 | 29 | 30 | 12 | 40 | 3 | 64 | 68 | 16 | 53.5 | No available data | 1 | 2 | 0 | 0 |
| Ki-67 expression | <14% | 26 | 27.5 | 5 | 16.5 | 0.0761 | 14–30% | 29 | 31 | 10 | 33.5 | >30% | 28 | 30 | 13 | 43.5 | No available data | 11 | 11.5 | 2 | 6.5 |
| Vimentin expression assessed | Yes | 82 | 87 | 26 | 86.5 | 0.8361 | No | 12 | 13 | 4 | 13.5 |
| Vimentin | Positive | 14 | 15 | 8 | 26.5 | 0.0372 | Negative | 68 | 85 | 18 | 73.5 |
| Contralateral breast cancer | 13 | 14 | 8 | 26.5 | 0.0228 | Other primary cancer (other than contralateral breast cancer) | 9 | 9.5 | 5 | 16.5 | 0.1475 |
|
|
FISH: fluorescence in situ hybridization.
|